Additionally, Mr. Jabbour will discuss MAT9001, the Company’s proprietary prescription-only omega-3 fatty acid-based composition under development for hypertriglyceridemia (TG>500 mg/dL), which has demonstrated statistically significant superiority versus Vascepa® (icosapent ethyl) in reducing serum triglycerides, total- and non-HDL-cholesterol, apolipoproteins and PCSK9 levels. MAT9001 is a next-generation omega-3 fatty acid composition, comprising docosapentaenoic acid (DPA), a potent but less prevalent omega-3 fatty acid with very unique properties, and other omega-3 fatty acids. MAT9001 was developed based on the newest scientific advancements in the field, incorporating and building upon the knowledge of almost 40 years of scientific research in the omega-3 discipline. Given recently announced developments in the cardiovascular space and the potential best-in-class data generated by MAT9001 to date, Matinas is well prepared to be opportunistic in evaluating strategic alternatives to further develop and commercialize MAT9001 on a global and/or regional basis.
Market Data 
Markets 
AI
